<DOC>
	<DOCNO>NCT02376777</DOCNO>
	<brief_summary>Differences efficacy safety new oral anticoagulant ( NOAC ) vitamin K antagonist ( VKA ) real practice remain uncertain . The exist ambulatory study answer NOAC specific issue , prescription habit motif , patient characteristic , biological monitoring , well occurrence major minor thromboembolic event , especially France warfarin less frequently prescribe . Therefore , order describe clinical follow characteristic patient receive oral anticoagulant , investigator set national prospective cohort compare occurrence thromboembolic event VKA NOAC primary care .</brief_summary>
	<brief_title>Comparison Accidents Their Circumstances With Oral Anticoagulants</brief_title>
	<detailed_description>The method include use national prospective observational cohort , involve 444 general practitioner From april december 2014 , health data adult patient consult general practitioner receive oral anticoagulant treatment enter database . Each patient receive information agreement participate study ( agreement stastical analysis health data one year follow ) . In March 2015 , half patient choose ( stratification ) , use match stratification process , follow one year . Every three month , data regard occurrence therapeutic change , episode excessive bleeding , thromboembolic event collect general practitioner . The data analyse : - describe characteristic patient receive oral anticoagulant treatment ; - describing change medication year ; - compare occurrence episode excessive bleeding ; - compare occurrence thromboembolic event patient use VKA versus patient use NOAC .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Embolism Thrombosis</mesh_term>
	<mesh_term>Hemorrhagic Disorders</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Inclusion Criteria : Patient consult GP Patient Whatever reason consultation Aged &gt; 18 year Receiving oral anticoagulant treatment NOAC ( apixaban , dabigatran rivaroxaban ) VKA ( acenocoumarol , fluindione , warfarin ) Whatever indication ( prevention treatment ) . Having follow indication anticoagulant treatment : nonvalvular atrial fibrillation , prevention DVT / PE ( exclude orthopedic postsurgery ) treatment DVT / PE Exclusion Criteria : Aged &lt; 18 year Receiving concomitant injectable anticoagulant treatment ( include relay phase ) Follow impossible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Anticoagulants</keyword>
	<keyword>Antithrombins</keyword>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Intracranial haemorrhage</keyword>
	<keyword>Gastrointestinal haemorrhage</keyword>
	<keyword>Myocardial infarction</keyword>
	<keyword>Stroke</keyword>
	<keyword>Venous thrombosis</keyword>
	<keyword>Primary care</keyword>
</DOC>